Top Markets
Coin of the day
Silo Pharma, Inc. Silo Pharma, Inc.

Silo Pharma, Inc.

SILO
Rangering i aksjer #35574
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm... Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Aksjekurs
$3.29
Sist synkronisert: 2026-08-14
Markedsverdi
$3.71M
Endring (1 dag)
2.17%
Endring (1 år)
-69.11%
Land
US
Handel Silo Pharma, Inc. (SILO)

Kategori

EPS for Silo Pharma, Inc. (SILO)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Silo Pharma, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Silo Pharma, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter